ZA200601822B - Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydrox-ymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same - Google Patents

Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydrox-ymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same

Info

Publication number
ZA200601822B
ZA200601822B ZA200601822A ZA200601822A ZA200601822B ZA 200601822 B ZA200601822 B ZA 200601822B ZA 200601822 A ZA200601822 A ZA 200601822A ZA 200601822 A ZA200601822 A ZA 200601822A ZA 200601822 B ZA200601822 B ZA 200601822B
Authority
ZA
South Africa
Prior art keywords
ymethyl
hydrox
hydroxy
ester
pharmaceutical compositions
Prior art date
Application number
ZA200601822A
Other languages
English (en)
Inventor
Eric J Benjamin
Jain Ashwinkumar
Ashraf Muhammad
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200601822(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200601822B publication Critical patent/ZA200601822B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
ZA200601822A 2003-09-03 2006-03-02 Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydrox-ymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same ZA200601822B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49978903P 2003-09-03 2003-09-03

Publications (1)

Publication Number Publication Date
ZA200601822B true ZA200601822B (en) 2008-12-31

Family

ID=34272870

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200601822A ZA200601822B (en) 2003-09-03 2006-03-02 Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydrox-ymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same

Country Status (25)

Country Link
US (2) US7271177B2 (xx)
EP (1) EP1660081A1 (xx)
JP (1) JP2007504226A (xx)
KR (1) KR20060090803A (xx)
CN (1) CN1874771A (xx)
AR (1) AR045559A1 (xx)
AU (1) AU2004270154A1 (xx)
BR (1) BRPI0414066A (xx)
CA (1) CA2536775A1 (xx)
CO (1) CO5680426A2 (xx)
CR (1) CR8293A (xx)
EC (1) ECSP066473A (xx)
GT (1) GT200400175A (xx)
IL (1) IL173786A0 (xx)
MX (1) MXPA06002123A (xx)
NO (1) NO20061048L (xx)
PA (1) PA8611201A1 (xx)
PE (1) PE20050945A1 (xx)
RU (1) RU2345999C2 (xx)
SA (1) SA04250334B1 (xx)
SG (1) SG145716A1 (xx)
TW (1) TW200510428A (xx)
UA (1) UA84881C2 (xx)
WO (1) WO2005023254A1 (xx)
ZA (1) ZA200601822B (xx)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536775A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
PL1701698T3 (pl) * 2004-01-08 2008-03-31 Wyeth Corp Prasowana bezpośrednio kompozycja farmaceutyczna do podawania doustnego CCI-779
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
EP1737869A1 (en) 2004-04-14 2007-01-03 Wyeth a Corporation of the State of Delaware Regiospecific synthesis of rapamycin 42-ester derivatives
BRPI0510277A (pt) * 2004-04-27 2007-10-30 Wyeth Corp método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
US7393952B2 (en) 2004-08-27 2008-07-01 Cordis Corporation Solvent free amorphous rapamycin
KR20070083839A (ko) * 2004-09-29 2007-08-24 코디스 코포레이션 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태
CA2595766A1 (en) 2005-02-09 2006-08-17 Wyeth Cci-779 polymorph and use thereof
CA2630784A1 (en) * 2005-12-07 2007-06-14 Wyeth Process for the preparation of purified crystalline cci-779
KR20080077147A (ko) * 2005-12-07 2008-08-21 와이어쓰 결정성 라파마이신의 제조 방법 및 시차 주사 열량계를사용하는 라파마이신 화합물의 결정화도의 측정 방법
RU2008120670A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Масштабируемый способ получения 42-сложного эфира рапамицина из 42-сложного эфира рапамицина бороната
JPWO2007072869A1 (ja) * 2005-12-21 2009-06-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 １，２−ジヒドロピリジン化合物の非晶質体
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080234657A1 (en) * 2007-03-22 2008-09-25 Medtronic Vascular, Inc. Methods for contributing to cardiovascular treatments
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
US8852620B2 (en) 2007-07-20 2014-10-07 Medtronic Vascular, Inc. Medical devices comprising polymeric drug delivery systems with drug solubility gradients
US20090269480A1 (en) * 2008-04-24 2009-10-29 Medtronic Vascular, Inc. Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
DK2365802T3 (da) 2008-11-11 2017-11-13 Univ Texas Mikrokapsler af rapamycin og anvendelse til behandling af cancer
US20100227799A1 (en) * 2009-03-09 2010-09-09 Medtronic Vascular, Inc. Simultaneous photodynamic therapy and photo induced polymerization
US8461172B2 (en) * 2009-05-12 2013-06-11 Corcept Therapeutics, Inc. Solid forms and process for preparing
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CN103298343A (zh) 2011-01-07 2013-09-11 科赛普特治疗公司 类固醇和糖皮质激素受体拮抗剂组合疗法
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
EP3039011A1 (en) * 2013-08-29 2016-07-06 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
PL3074011T3 (pl) 2013-11-25 2020-01-31 Corcept Therapeutics Incorporated Połączone fuzyjnie oktahydro związki azadekaliny jako modulatory receptora glukokortykoidowego
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
WO2018213352A1 (en) 2017-05-15 2018-11-22 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス，インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132023A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
EP3927345A4 (en) 2019-02-22 2022-12-21 Corcept Therapeutics Incorporated THERAPEUTIC USES OF RELACORILANT, A GLUCOCORTICOID RECEPTOR MODULATOR DERIVED FROM AZADECALIN FUSED TO A HETEROARYL KETONE
WO2020209828A1 (en) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
CA3158745A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
TWI256395B (en) * 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
SI1635830T1 (sl) 2002-09-17 2009-02-28 Wyeth Corp Granulirana farmacevtska oblika rapamicin-estra cci-779
CN1829722B (zh) * 2003-08-07 2010-10-27 惠氏公司 区域选择性合成cci-779
CA2536775A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
PL1701698T3 (pl) 2004-01-08 2008-03-31 Wyeth Corp Prasowana bezpośrednio kompozycja farmaceutyczna do podawania doustnego CCI-779

Also Published As

Publication number Publication date
NO20061048L (no) 2006-05-24
SG145716A1 (en) 2008-09-29
SA04250334B1 (ar) 2008-05-19
AU2004270154A1 (en) 2005-03-17
US20050049271A1 (en) 2005-03-03
PA8611201A1 (es) 2005-05-10
CO5680426A2 (es) 2006-09-29
US20080070950A1 (en) 2008-03-20
RU2345999C2 (ru) 2009-02-10
GT200400175A (es) 2005-04-18
PE20050945A1 (es) 2005-12-14
UA84881C2 (ru) 2008-12-10
JP2007504226A (ja) 2007-03-01
KR20060090803A (ko) 2006-08-16
CA2536775A1 (en) 2005-03-17
ECSP066473A (es) 2006-10-10
CN1874771A (zh) 2006-12-06
MXPA06002123A (es) 2006-05-17
TW200510428A (en) 2005-03-16
BRPI0414066A (pt) 2006-10-24
US7446111B2 (en) 2008-11-04
CR8293A (es) 2006-07-14
EP1660081A1 (en) 2006-05-31
WO2005023254A1 (en) 2005-03-17
US7271177B2 (en) 2007-09-18
AR045559A1 (es) 2005-11-02
RU2006110568A (ru) 2007-10-10
IL173786A0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
ZA200601822B (en) Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydrox-ymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
HUS2100052I1 (hu) Tienopirimidin-vegyületek és alkalmazásuk
IL241211B (en) History of itansinoid and pharmaceutical preparations containing them
IL178294A0 (en) Thienopyridine derivatives and pharmaceutical compositions containing the same
IL179207A0 (en) Pyrrole derivatives and pharmaceutical compositions containing the same
EP1601524A4 (en) INTRALUMINAL PROSTHESIS WITH TEMPERED POLYMER COVER
IL163711A0 (en) Macrocyclic compounds useful as pharmaceuticals
EP1573833A4 (en) NANOFILM COMPOSITIONS WITH POLYMERIC COMPONENTS
AU2003278410A1 (en) Charging device
IL173813A0 (en) Rifamycin analogs and uses thereof
AU2003215405A1 (en) Ureteral stent
AU2003300099A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta
AU2003219422A1 (en) Reminder handling
PL2116249T3 (pl) Kompozycja farmaceutyczna zawierająca gestageny, i/lub estrogeny i 5-metylo-(6S)-tetrahydrofolian
IL165388A0 (en) Macrolide compounds and pharmaceutical compositions containing the same
IL172814A0 (en) Novel solid pharmaceutical composition comprising amisulpride
EP1701962A4 (en) RIFAMYCIN ANALOGS AND USES THEREOF
IL170705A0 (en) Polymeric crosslinkable compositions containing acetal amides
EP1726008A4 (en) BIS-PROPYLAMINE ANALOG AND COMPOSITION
EP1697382A4 (en) ANALOGUES OF RIFAMYCIN AND USES THEREOF
TWI318992B (en) Superabsorbent polymer with slow absorption times
IL156615A0 (en) Pharmaceutical compositions with antibiotic activity
AU2003294063A1 (en) Polymeric adsorbing structure
GB0310365D0 (en) Polymeric composition
AU2003263457A1 (en) Hinge device with predetermined moving sequence